Cargando…

Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report

Much excitement has been generated with the approval of idarucizumab, a humanized monoclonal antigen‐binding antibody fragment that is capable of reversing the anticoagulant activity of dabigatran. Here, we describe our initial experience of using tissue plasminogen activator (tPA) in an acute poste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mutzenbach, Johannes Sebastian, Pikija, Slaven, Otto, Ferdinand, Halwachs, Ursula, Weymayr, Friedrich, Sellner, Johann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Case Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099535/ https://www.ncbi.nlm.nih.gov/pubmed/27844035 http://dx.doi.org/10.1002/acn3.346

Ejemplares similares

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence
por: Pikija, Slaven, et al.
Publicado: (2017)

Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report
por: Xie, Dan, et al.
Publicado: (2021)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
por: Kafke, Waldemar, et al.
Publicado: (2016)

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
por: Agosti, Sergio, et al.
Publicado: (2017)

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature
por: Frol, Senta, et al.
Publicado: (2021)

Intracranial Thrombus Morphology and Composition Undergoes Time-Dependent Changes in Acute Ischemic Stroke: A CT Densitometry Study
por: Pikija, Slaven, et al.
Publicado: (2016)

Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
por: Vukorepa, Gorana, et al.
Publicado: (2020)

Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
por: Binet, Quentin, et al.
Publicado: (2018)

Reversal of Anticoagulation Effect of Dabigatran with Idarucizumab, for Thrombolysis in Acute Ischemic Stroke: Inimicus Inimico Amicus
por: Maramattom, Boby V., et al.
Publicado: (2019)

Endovascular Therapy for Tandem Occlusion in Acute Ischemic Stroke: Intravenous Thrombolysis Improves Outcomes
por: Pikija, Slaven, et al.
Publicado: (2019)

Fibrinogen consumption is related to intracranial clot burden in acute ischemic stroke: a retrospective hyperdense artery study
por: Pikija, Slaven, et al.
Publicado: (2016)

Contribution of Serum Lipid Profiles to Outcome After Endovascular Thrombectomy for Anterior Circulation Ischemic Stroke
por: Pikija, Slaven, et al.
Publicado: (2018)

Neutrophil to lymphocyte ratio predicts intracranial hemorrhage after endovascular thrombectomy in acute ischemic stroke
por: Pikija, Slaven, et al.
Publicado: (2018)

Antiplatelet Usage Impacts Clot Density in Acute Anterior Circulation Ischemic Stroke
por: Pikija, Slaven, et al.
Publicado: (2016)

Idarucizumab: A novel antidote for reversal of dabigatran
por: Rehman, Abdul, et al.
Publicado: (2016)

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage
por: Balakumar, Jonathan, et al.
Publicado: (2017)

Reversal of the Anticoagulation Effects of Dabigatran Etexilate by Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke
por: von Wowern, Fredrik, et al.
Publicado: (2017)

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
por: Glund, Stephan, et al.
Publicado: (2018)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases
por: Vosko, Milan R., et al.
Publicado: (2017)

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy
por: Kikule, Ilga, et al.
Publicado: (2022)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
por: Hieber, Maren, et al.
Publicado: (2019)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Idarucizumab for the treatment of dabigatran-related nephropathy
por: Alsamarrai, Ammar, et al.
Publicado: (2020)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
por: Proietti, Marco, et al.
Publicado: (2018)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
por: Abdulrehman, Jameel, et al.
Publicado: (2021)

Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report
por: Gawehn, Annemarie, et al.
Publicado: (2016)

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2018)

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
por: Gendron, Nicolas, et al.
Publicado: (2017)

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
por: Norris, Stephen, et al.
Publicado: (2017)

Higher Blood Pressure during Endovascular Thrombectomy in Anterior Circulation Stroke Is Associated with Better Outcomes
por: Pikija, Slaven, et al.
Publicado: (2018)

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
por: Held, Valentin, et al.
Publicado: (2016)

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
por: Edwards, Gail, et al.
Publicado: (2017)

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
por: Song, Steven, et al.
Publicado: (2017)

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
por: Tralhão, António, et al.
Publicado: (2017)

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
por: Ströhle, Mathias, et al.
Publicado: (2021)

Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report
por: Jia, Yu, et al.
Publicado: (2022)

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report
por: Ohtani, Toshiyuki, et al.
Publicado: (2019)

Idarucizumab for dabigatran reversal in cardiac tamponade complicating percutaneous intervention in ST elevation myocardial infarction
por: Kurdziel, Marta, et al.
Publicado: (2021)

Idarucizumab (Praxbind(®)) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients
por: Kalmanovich, Eran, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o0dkt0cjddnbgga393pkp779go